The role of PGE2 receptor EP4 in pathologic ocular angiogenesis

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 11, 2009, Pages 5479-5486

  Yanni, Susan E ^a   Barnett, Joshua M ^b   Clark, Monika L ^a   Penn, John S ^a,b,c  

^a Departments of Cell and Developmental Biology   (United States)

^b Pharmacology   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L 161982; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; CYCLOOXYGENASE 2; L-161982; OXYGEN; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PTGER4 PROTEIN, HUMAN; PTGER4 PROTEIN, MOUSE; PTGER4 PROTEIN, RAT; PTGS2 PROTEIN, MOUSE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL INFILTRATION; CELL PROLIFERATION; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; MUELLER CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINA CELL; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; ANIMAL; BROWN NORWAY RAT; CHEMICALLY INDUCED DISORDER; CHOROID; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GLIA; LASER COAGULATION; MALE; METABOLISM; NEWBORN; PHYSIOLOGY; RAT; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; CELL PROLIFERATION; CHOROID; CHOROIDAL NEOVASCULARIZATION; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LASER COAGULATION; MALE; MICE; NEUROGLIA; OXYGEN; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; THIOPHENES; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953359022     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3652     Document Type: Article

References (44)

1. Li WW, Talcott KE, Zhai AW, et al. The role of therapeutic angiogenesis in tissue repair and regeneration. Adv Skin Wound Care. 2005;18:491-500.
2. Rahmani B, Tielsch JM, Kat J, et al. The cause-specific prevalence of visual impairment in an urban population: the Baltimore Eye Survey. Ophthalmology. 1999;103:1721-1726.
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
4. Steinkuller PG, Du L, Gilbert C, et al. Childhood blindness. J AAPOS. 1999;3:26-32.
5. D'Amore PA. Mechanisms of retinal and choroidal angiogenesis. Invest Ophthalmol Vis Sci. 1994;35:3974-3979.
6. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997;124:521-529.
7. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalomol. 1995;113:1538-1544.
8. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-909.
9. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
10. Robbins SG, Conaway JR, Ford BL, et al. Detection of VEGF protein in vascular and non-vascular cells of the normal and oxygeninjured retina. Growth Factors. 1997;14:229-241.
11. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation of vascular endothelial cell growth factor by hypoxia. Growth Factors. 1998;16:1-9.
12. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9:777-794.
13. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276:3222-3230.
14. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 998;58:409-412.
15. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene. 1999;18: 7908-7916.
16. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med. 1983;172:214-218.
17. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69:475-482.
18. Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol. 1994;9:807-843.
19. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147-166.
20. Hatazawa R, Tanaka A, Tanigami M, et al. Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol. 2007;293: G788-G797.
21. Hatazawa R, Tanigami M, Izumi N, et al. Prostaglandin E2 stimulates VEGF expression in primary rat gastric fibroblasts through EP4 receptors. Inflammopharmacology. 2007;15:214-217.
22. Rao R, Redha R, Macias-Perez I, et al. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem. 2007;282:16959-16968.
23. Kabashima K, Sakata D, Nagamachi M, et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med. 2003;9:744-749.
24. Cherukuri DP, Chen XB, Goulet AC, et al. The EP4 receptor antagonist, L-161982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res. 2007;313:2969-2979.
25. Hawcroft G, Ko CW, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene. 2007;26:3006-3019.
26. Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem. 2004;279:29797-29804.
27. Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 2006; 66:2923-2927.
28. Muller M, Sales KJ, Katz AA, et al. Seminal plasma promotes the expression of tumorigenic and angiogenic genes in cervical adenocarcinoma cells via the E-series prostanoid 4 receptor. Endocrinology. 2006;147:3356-3365.
29. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res. 2006;66:9665-9672.
30. Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res. 2006;66:3106-3113.
31. Kitamura T, Itoh M, Noda T, et al. Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci. 2003;94:618-621.
32. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002;62:28-32.
33. Hicks D, Curtois Y. The growth and behaviour of rat retinal Müller cells in vitro, 1: an improved method for isolation and culture. Exp Eye Res. 1990;51:119-129.
34. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;26:724-731.
35. Barnett JM, McCollum GW, Fowler JA, et al. Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Invest Ophthalmol Vis Sci. 2007; 28:907-915.
36. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-585.
37. Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174:491-497.
38. Inoue H, Takamori M, Shimoyama Y, et al. Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol. 2002;136:287-295.
39. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem. 2004;279:46700-46705.
40. Bradbury D, Clarke D, Seedhouse C, et al. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem. 2005;280:29993-30000.
41. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun. 2002;294:441-447.
42. Lonchampt M, Pennel L, Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest Ophthalmol Vis Sci. 2001;42:429-432.
43. Nagai N, Noda K, Urano T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci. 2005;46:1078-1084.
44. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007;26:525-534.